Iovance Biotherapeutics Future Growth

Future criteria checks 5/6

Iovance Biotherapeutics is forecast to grow earnings and revenue by 61.7% and 43.7% per annum respectively while EPS is expected to grow by 64.5% per annum.

Key information

61.7%

Earnings growth rate

64.5%

EPS growth rate

Biotechs earnings growth	24.7%
Revenue growth rate	43.7%
Future return on equity	n/a
Analyst coverage	Good
Last updated	21 Apr 2024

Recent future growth updates

Recent updates

Iovance Biotherapeutics: Riding The Favorable Moment Could Bring Excellent Results

Apr 09

Iovance Biotherapeutics: Initial Amtagvi Launch In Focus

Mar 25

Iovance Biotherapeutics: Amtagvi's Pioneering Approval Sets New Standards In Melanoma

Feb 20

Iovance Biotherapeutics: Preparing For Volatility Around Lifileucel's Upcoming PDUFA Date

Jan 19

Iovance Biotherapeutics Approaches Key Regulatory Milestone As Clinical Momentum Accelerates

Sep 27

Iovance submits rolling license application to FDA for skin cancer treatment lifileucel

Aug 25

Iovance Biotherapeutics: An Unproven Biopharmaceutical Company With Significant Upside

Mar 25

Iovance Biotherapeutics: Uncertainty And Opportunity

Dec 05

Iovanve Biotherapeutics (IOVA) Presents At 2021 ASCO Annual Virtual Meeting - Slideshow

Jun 16

Iovance Bio reports 33-month follow up data for lifileucel in advanced melanoma at ASCO21

Jun 07

Iovance: Down And Rebound

May 30

Here's Why We're Not Too Worried About Iovance Biotherapeutics' (NASDAQ:IOVA) Cash Burn Situation

Mar 16

Earnings and Revenue Growth Forecasts

NasdaqGM:IOVA - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	685	7	101	222	8
12/31/2025	413	-245	-154	-64	12
12/31/2024	161	-352	-267	-222	13
12/31/2023	1	-444	-384	-362	N/A
9/30/2023	1	-433	-377	-356	N/A
6/30/2023	0	-419	-355	-335	N/A
3/31/2023	N/A	-412	-333	-319	N/A
12/31/2022	N/A	-396	-313	-293	N/A
9/30/2022	N/A	-390	-294	-269	N/A
6/30/2022	N/A	-376	-296	-263	N/A
3/31/2022	N/A	-358	-278	-239	N/A
12/31/2021	N/A	-342	-266	-228	N/A
9/30/2021	N/A	-311	-290	-237	N/A
6/30/2021	N/A	-284	-281	-220	N/A
3/31/2021	N/A	-265	-259	-202	N/A
12/31/2020	N/A	-260	-252	-205	N/A
9/30/2020	N/A	-255	-223	-196	N/A
6/30/2020	N/A	-246	-208	-198	N/A
3/31/2020	N/A	-230	-202	-195	N/A
12/31/2019	N/A	-198	-166	-159	N/A
9/30/2019	N/A	-167	-140	-137	N/A
6/30/2019	N/A	-151	-125	-122	N/A
3/31/2019	N/A	-134	-114	-112	N/A
12/31/2018	N/A	-124	-102	-101	N/A
9/30/2018	N/A	-117	-92	-91	N/A
6/30/2018	N/A	-105	-85	-84	N/A
3/31/2018	N/A	-98	-78	-78	N/A
12/31/2017	N/A	-92	-80	-79	N/A
9/30/2017	N/A	-82	N/A	-70	N/A
6/30/2017	N/A	-128	N/A	-61	N/A
3/31/2017	N/A	-116	N/A	-47	N/A
12/31/2016	N/A	-102	N/A	-33	N/A
9/30/2016	N/A	-95	N/A	-27	N/A
6/30/2016	N/A	-34	N/A	-19	N/A
3/31/2016	N/A	-29	N/A	-19	N/A
12/31/2015	N/A	-28	N/A	-18	N/A
9/30/2015	N/A	-24	N/A	-15	N/A
6/30/2015	N/A	-19	N/A	-13	N/A
3/31/2015	N/A	-15	N/A	-10	N/A
12/31/2014	N/A	-12	N/A	-9	N/A
9/30/2014	N/A	-27	N/A	-8	N/A
6/30/2014	N/A	-34	N/A	-6	N/A
3/31/2014	N/A	-35	N/A	-6	N/A
12/31/2013	N/A	-34	N/A	-4	N/A
9/30/2013	N/A	-10	N/A	-1	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: IOVA is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.4%).

Earnings vs Market: IOVA is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: IOVA is expected to become profitable in the next 3 years.

Revenue vs Market: IOVA's revenue (43.7% per year) is forecast to grow faster than the US market (8.3% per year).

High Growth Revenue: IOVA's revenue (43.7% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if IOVA's Return on Equity is forecast to be high in 3 years time

Iovance Biotherapeutics Future Growth

Future criteria checks 5/6

Key information

Recent future growth updates

Consensus revenue estimates increase by 11%

Price target increased by 19% to US$24.42

Consensus revenue estimates decrease by 25%

Price target decreased by 8.7% to US$20.42

Consensus revenue estimates decrease by 71%

Price target decreased by 8.9% to US$22.36

Recent updates

Iovance Biotherapeutics, Inc. to Report Q1, 2024 Results on May 09, 2024

Iovance Biotherapeutics, Inc., Annual General Meeting, Jun 11, 2024

Iovance Biotherapeutics: Riding The Favorable Moment Could Bring Excellent Results

Iovance Biotherapeutics, Inc. Agrees to A Proposed Settlement

Iovance Biotherapeutics: Initial Amtagvi Launch In Focus

Consensus revenue estimates increase by 11%

Iovance Biotherapeutics Announces Fda Has Lifted Clinical Hold on the Iov-Lun-202 Registrational Trial in Non-Small Cell Lung Cancer

New minor risk - Profitability

Iovance Biotherapeutics, Inc. to Report Q4, 2023 Results on Feb 28, 2024

New major risk - Share price stability

Iovance Biotherapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $210.5781 million.

Price target increased by 19% to US$24.42

Iovance Biotherapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $210.5781 million.

Iovance Biotherapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $210.5781 million.

Iovance Biotherapeutics: Amtagvi's Pioneering Approval Sets New Standards In Melanoma

Consensus revenue estimates decrease by 25%

Iovance Biotherapeutics, Inc.’s AMTAGVI™ (lifileucel) Receives U.S. FDA Accelerated Approval for Advanced Melanoma

New minor risk - Profitability

Iovance Biotherapeutics: Preparing For Volatility Around Lifileucel's Upcoming PDUFA Date

Iovance Biotherapeutics, Inc. Announces Clinical Program Update for LN-145 in Non-Small Cell Lung Cancer

Price target decreased by 8.7% to US$20.42

Consensus revenue estimates decrease by 71%

Iovance Biotherapeutics, Inc. to Report Q3, 2023 Results on Nov 07, 2023

New major risk - Financial position

Independent Director recently bought US$27m worth of stock

Iovance Biotherapeutics, Inc. Announces U.S. Food and Drug Administration Updates

Price target decreased by 8.9% to US$22.36

Consensus revenue estimates decrease by 62%, EPS upgraded

New minor risk - Financial position

Iovance Biotherapeutics, Inc. to Report Q2, 2023 Results on Aug 08, 2023

New major risk - Shareholder dilution

Iovance Biotherapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $150 million.

Iovance Biotherapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $150 million.

Price target increased by 13% to US$24.55

Iovance Biotherapeutics Announces First Patient Randomized in Phase 3 TILVANCE-301 Trial in Frontline Advanced Melanoma

Consensus revenue estimates decrease by 21%, EPS upgraded

Iovance Biotherapeutics, Inc. Announces U.S. Food and Drug Administration Accepts the Biologics License Application of Lifileucel for the Treatment of Advanced Melanoma

Consensus revenue estimates increase by 1,282%, EPS downgraded

Consensus revenue estimates decrease by 84%, EPS upgraded

Insufficient new directors

Consensus revenue estimates decrease by 15%, EPS upgraded

Iovance Biotherapeutics, Inc. (NasdaqGM:IOVA) entered into a definitive agreement to acquire Worldwide rights of Proleukin of Clinigen Limited fo

Interim CEO exercised options and sold US$234k worth of stock

Chief Medical Officer exercised options and sold US$67k worth of stock

Price target decreased to US$23.00

Independent Director recently bought US$62k worth of stock

Independent Director recently bought US$65m worth of stock

Price target decreased to US$23.77

Independent Director recently bought US$62k worth of stock

Iovance Biotherapeutics, Inc. Provides Update on Biologics License Application Submission for Lifileucel in Advanced Melanoma

Iovance Biotherapeutics, Inc. Announces Updated Clinical Data for Lifileucel in Advanced Melanoma At Society for Immunotherapy of Cancer (Sitc) Annual Meeting

Iovance Biotherapeutics, Inc. Announces Updated Clinical Data for Lifileucel in Advanced Melanoma At Society for Immunotherapy of Cancer (SITC) Annual Meeting

Iovance Biotherapeutics, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Iovance Biotherapeutics, Inc. Announces First Patient Dosed with PD-1 Inactivated Tumor Infiltrating Lymphocyte Therapy

Iovance Biotherapeutics Approaches Key Regulatory Milestone As Clinical Momentum Accelerates

Independent Director exercised options to buy US$440k worth of stock.

Iovance Biotherapeutics Initiates Biologics License Application (BLA) Submission for Lifileucel in Advanced Melanoma

Iovance submits rolling license application to FDA for skin cancer treatment lifileucel

Calculating The Fair Value Of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)

Price target decreased to US$25.17

Iovance Biotherapeutics falls 6% on Q2 2022 bottom line miss

Iovance: TIL Cell Therapy Set To Prove Itself

Iovance Biotherapeutics, Inc.(NasdaqGM:IOVA) dropped from Russell 1000 Dynamic Index

Iovance Biotherapeutics, Inc. Appoints Wendy L. Dixon to Board of Directors

Independent Director recently bought US$51k worth of stock

Price target decreased to US$30.77

Iovance Biotherapeutics Announces Positive Clinical Data for Lifileucel in Advanced Melanoma

Iovance: Onward To Approval

Iovance Biotherapeutics, Inc. Announces Regulatory and Clinical Updates for Lifileucel in Melanoma